PMCPA PRESS RELEASE 17 April 2026 - Cases ruled in breach of Clause 2
THERAMEX HQ UK LTD has breached the ABPI Code of Practice for the Pharmaceutical Industry and brought discredit upon, and reduced confidence in, the pharmaceutical industry. In addition, THERAMEX HQ UK LTD was publicly reprimanded.
17 April 2026
THERAMEX HQ UK LTD – Case/0265/08/24
For failure to state the contraindication in pregnancy on Yselty (linzagolix) advertising material at a reproduction and embryology conference, coupled with an inaccurate indication statement on the stand and missing obligatory information, THERAMEX UK LTD was ruled in breach of the following clauses of the 2021 Code:
Clause 2 - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry
Clause 5.1 - Failing to maintain high standards
Clause 6.1 - Providing misleading information
Clause 11.2 - Promotion inconsistent with the SPC
Clause 12.1 - Failing to include prescribing information
Clause 12.9 - Failing to include an adverse event reporting statement
On 28 January 2026, THERAMEX UK LTD communicated that it would no longer accept the jurisdiction of the PMCPA and left self-regulation. The Medicines and Healthcare products Regulatory Agency (MHRA) was informed of the position.
THERAMEX HQ UK LTD – Case/0303/09/24 – PUBLIC REPRIMAND
For the fundamental compliance errors highlighted by this case, including failing to provide up-to-date prescribing information for the Evorel (estradiol) range and Intrarosa (prasterone) for several years, Theramex HQ UK Ltd was publicly reprimanded by the Code of Practice Appeal Board. The Appeal Board had no evidence before it to show that Theramex had taken any action to improve since this case was reported to the Appeal Board by the Code of Practice Panel and considered by the Appeal Board in May 2025. By leaving the self-regulatory framework and requiring the MHRA to assume full responsibility for regulating it, Theramex has inevitably delayed any regulatory action and oversight. In addition to the public reprimand, the Appeal Board also required an audit of Theramex's procedures in relation to the ABPI Code to be carried out by the PMCPA. Theramex must comply with the requirement for a PMCPA audit should it request to rejoin self-regulation in the future.
The case reports and public reprimand are available at www.pmcpa.org.uk.
Ends
Notes to Editors:
The advertisement will appear in the BMJ and the Nursing Standard in June 2026.
Media Contacts:
For more information contact info@pmcpa.org.uk
The Prescription Medicines Code of Practice Authority (PMCPA) is the self-regulatory body for the pharmaceutical industry in the UK and was established by The Association of the British Pharmaceutical Industry (ABPI) to operate the ABPI Code of Practice for the Pharmaceutical Industry independently of the ABPI. The PMCPA is a division of the ABPI. The Code covers the promotion of medicines for prescribing to health professionals and the provision of information to the public about prescription only medicines.
If you have any concerns about the activities of pharmaceutical companies in this regard, please contact the PMCPA at 2nd Floor, Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB, email: complaints@pmcpa.org.uk, or visit www.pmcpa.org.uk/complaints-procedure/make-a-complaint.
The Code and other information, including details about ongoing cases, can be found on the PMCPA website: www.pmcpa.org.uk.
The PMCPA is a division of the ABPI which is a company limited by guarantee registered in England & Wales no 09826787. Registered office 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.